

January 4, 2017



## OPKO Health to Present at the J.P. Morgan 35th Annual Healthcare Conference

MIAMI, Jan. 04, 2017 (GLOBE NEWSWIRE) -- **OPKO Health, Inc.** (NASDAQ:OPK) today announced that senior management will present at the J.P. Morgan 35<sup>th</sup> Annual Healthcare Conference on Wednesday, January 11, 2017 at 9:00 AM (PT).

The presentation will be webcast on the OPKO Investor Relations page of the corporate website at [www.opko.com](http://www.opko.com). To access the live webcast please log on to the OPKO site approximately fifteen minutes before the presentation to register and download any necessary audio software. The audio presentation will be available at this link for a limited time after the live presentation.

### **About OPKO Health, Inc.**

OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation PDUFA date: January 2017), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in phase 2a) and a long-acting oxyntomodulin for diabetes and obesity (in phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at [www.opko.com](http://www.opko.com).

OPKO Health, Inc.  
Tara Mackay, 305-575-4100  
Investor Relations  
or  
Media  
Rooney & Associates  
Terry Rooney, 212-223-0689  
[trooney@rooneyco.com](mailto:trooney@rooneyco.com)  
or  
Marion Janic, 212-223-4017  
[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)  
or  
Investors  
LHA

Anne Marie Fields, 212-838-3777  
afields@lhai.com  
or  
Bruce Voss, 310-691-7100  
bvoss@lhai.com



Source: OPKO Health Inc.